NOW APPROVED – FOTIVDA® (tivozanib)

passionately pursuing a better life for patients with cancer. follow our pursuit

latest news

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)

###